{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:05Z","timestamp":1787387045249,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson and Johnson Innovative Medicine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03630-3","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T09:01:02Z","timestamp":1781254862000},"page":"4079-4103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis"],"prefix":"10.1007","volume":"43","author":[{"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6370-4951","authenticated-orcid":false,"given":"Ana\u00efs","family":"Lemyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7482-5270","authenticated-orcid":false,"given":"Qiaoyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4595-9675","authenticated-orcid":false,"given":"Carol","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-325X","authenticated-orcid":false,"given":"Todor I.","family":"Totev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9439-595X","authenticated-orcid":false,"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2906-9998","authenticated-orcid":false,"given":"Yujie","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5775-9590","authenticated-orcid":false,"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav","family":"Namjoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-5025","authenticated-orcid":false,"given":"John J.","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-7167","authenticated-orcid":false,"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2216-5442","authenticated-orcid":false,"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine C. El","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-9266","authenticated-orcid":false,"given":"Leslie","family":"Citrome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"3630_CR1","unstructured":"National Institute of Mental Health. Major depression statistics. Available from: https:\/\/www.nimh.nih.gov\/health\/statistics\/major-depression. Accessed 23 June 25."},{"key":"3630_CR2","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (5th ed.). 2013. Available from: https:\/\/doi.org\/10.1176\/appi.books.9780890425596. Accessed 12 Dec 2025.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"3630_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41572-023-00454-1","volume":"9","author":"W Marx","year":"2023","unstructured":"Marx W, Penninx BW, Solmi M, Furukawa TA, Firth J, Carvalho AF, et al. Major depressive disorder. Nat Rev Dis Primers. 2023;9(1):44.","journal-title":"Nat Rev Dis Primers"},{"key":"3630_CR4","unstructured":"American Psychological Association. American Psychological Association Clinical Practice Guidelines for the Treatment of Depression Across Three Age Cohorts. 2019. Available from: https:\/\/www.apa.org\/depression-guideline\/guideline.pdf. Accessed 12 Dec 2025."},{"issue":"2","key":"3630_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.7326\/M22-2056","volume":"176","author":"A Qaseem","year":"2023","unstructured":"Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I, Tufte J, Cross JT Jr, Wilt TJ, et al. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the american college of physicians. Ann Intern Med. 2023;176(2):239\u201352.","journal-title":"Ann Intern Med"},{"issue":"9","key":"3630_CR6","doi-asserted-by":"publisher","first-page":"4064","DOI":"10.1017\/S0033291722000745","volume":"53","author":"T Kishimoto","year":"2023","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Efficacy and safety\/tolerability of antipsychotics in the treatment of adult patients with major depressive disorder: a systematic review and meta-analysis. Psychol Med. 2023;53(9):4064\u201382.","journal-title":"Psychol Med"},{"key":"3630_CR7","unstructured":"US Food and Drug Administration. Drugs@FDA: FDA-approved drugs. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/. Accessed 23 June 2025."},{"issue":"3","key":"3630_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1176\/appi.ajp.20220504","volume":"180","author":"GS Sachs","year":"2023","unstructured":"Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M. Adjunctive Cariprazine for the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry. 2023;180(3):241\u201351.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"3630_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.4088\/JCP.15m10070","volume":"77","author":"S Durgam","year":"2016","unstructured":"Durgam S, Earley W, Guo H, Li D, Nemeth G, Laszlovszky I, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371\u20138.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"3630_CR10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.4088\/JCP.14m09688","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, Hobart M, Augustine C, Zhang P, et al. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76(9):1224\u201331.","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"3630_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.4088\/JCP.14m09689","volume":"76","author":"ME Thase","year":"2015","unstructured":"Thase ME, Youakim JM, Skuban A, Hobart M, Zhang P, McQuade RD, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232\u201340.","journal-title":"J Clin Psychiatry"},{"key":"3630_CR12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1017\/S1461145710000015","volume":"13","author":"N El-Khalili","year":"2010","unstructured":"El-Khalili N, Joyce M, Atkinson S, Buynak RJ, Datto C, Lindgren P, et al. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Int J Neuropsychopharmacol. 2010;13:917\u201332.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"3630_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.4088\/JCP.08m04629","volume":"70","author":"M Bauer","year":"2009","unstructured":"Bauer M, Pretorius HW, Constant EL, Earley W, Szamosi J, Brecher M. Extended-release Quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 2009;70(4):540\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"3630_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","volume":"28","author":"RN Marcus","year":"2008","unstructured":"Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind placebo-controlled study. J Clin Psychopharmacol. 2008;28(6):156\u201365.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"3630_CR15","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4088\/JCP.v68n0604","volume":"68","author":"RM Berman","year":"2007","unstructured":"Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(6):843\u201353.","journal-title":"J Clin Psychiatry"},{"key":"3630_CR16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2147\/TCRM.S117321","volume":"13","author":"M Solmi","year":"2017","unstructured":"Solmi M, Murru A, Pacchiarotti I, Undurraga J, Veronese N, Fornaro M, et al. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag. 2017;13:757\u201377.","journal-title":"Ther Clin Risk Manag"},{"key":"3630_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.781946","volume":"12","author":"P Mohr","year":"2021","unstructured":"Mohr P, Masopust J, Kopecek M. Dopamine receptor partial agonists: do they differ in their clinical efficacy? Front Psychiatry. 2021;12:781946.","journal-title":"Front Psychiatry"},{"issue":"2","key":"3630_CR18","first-page":"20","volume":"18","author":"DE Curry","year":"2022","unstructured":"Curry DE, Richards BL. A brief review of quetiapine. Am J Psychiatry. 2022;18(2):20\u20132.","journal-title":"Am J Psychiatry"},{"key":"3630_CR19","first-page":"30259","volume":"15","author":"SR Ahmad","year":"2025","unstructured":"Ahmad SR, Zeyaullah M, AlShahrani AM, Khan MS, Dawria A, Mohieldin A, et al. Unlocking the potential of lumateperone and novel anti-psychotics for schizophrenia. Bioimpacts. 2025;15:30259.","journal-title":"Bioimpacts"},{"key":"3630_CR20","unstructured":"SYMBYAX Prescribing Information. Lilly USA, LLC. Indianapolis, IN 46285, USA. 2025. Available from: https:\/\/pililly.com\/us\/symbyax-pi.pdf. Accessed 12 Dec 2025."},{"issue":"1","key":"3630_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-025-06783-7","volume":"25","author":"B Bai","year":"2025","unstructured":"Bai B, Li Y, Chen X, Huang J, Chen Q, Du X, et al. The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry. 2025;25(1):338.","journal-title":"BMC Psychiatry"},{"issue":"38","key":"3630_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034670","volume":"102","author":"J Wang","year":"2023","unstructured":"Wang J, Li W, Li M, Wu H, Qiu Z. Comparative efficacy and safety of 4 atypical antipsychotics augmentation treatment for major depressive disorder in adults: a systematic review and network meta-analysis. Medicine (Baltimore). 2023;102(38):e34670.","journal-title":"Medicine (Baltimore)"},{"key":"3630_CR23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","volume":"302","author":"NA Nunez","year":"2022","unstructured":"Nunez NA, Joseph B, Pahwa M, Kumar R, Resendez MG, Prokop LJ, et al. Augmentation strategies for treatment resistant major depression: a systematic review and network meta-analysis. J Affect Disord. 2022;302:385\u2013400.","journal-title":"J Affect Disord"},{"issue":"12","key":"3630_CR24","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1017\/S0033291722001246","volume":"52","author":"Y Yan","year":"2022","unstructured":"Yan Y, Yang X, Wang M, Chen B, Yin L, Ma X. Efficacy and acceptability of second-generation antipsychotics with antidepressants in unipolar depression augmentation: a systematic review and network meta-analysis. Psychol Med. 2022;52(12):2224\u201331.","journal-title":"Psychol Med"},{"issue":"11","key":"3630_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv060","volume":"18","author":"X Zhou","year":"2015","unstructured":"Zhou X, Keitner GI, Qin B, Ravindran AV, Bauer M, Del Giovane C, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. Int J Neuropsychopharmacol. 2015;18(11):pyv060.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"3630_CR26","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.4088\/JCP.14r09204","volume":"76","author":"X Zhou","year":"2015","unstructured":"Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487\u201398.","journal-title":"J Clin Psychiatry"},{"key":"3630_CR27","unstructured":"US Food and Drug Administration. FDA Online Label Repository. Available at: https:\/\/labels.fda.gov. Accessed 12 Dec 2025."},{"issue":"4","key":"3630_CR28","doi-asserted-by":"publisher","first-page":"25m15848","DOI":"10.4088\/JCP.25m15848","volume":"86","author":"S Durgam","year":"2025","unstructured":"Durgam S, Earley W, Kozauer SG, Chen C, Lakkis H, McIntyre RS, et al. Lumateperone as adjunctive therapy in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. J Clin Psychiatry. 2025;86(4):25m15848.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"3630_CR29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1176\/appi.ajp.20250292","volume":"182","author":"S Durgam","year":"2025","unstructured":"Durgam S, Earley WR, Kozauer SG, Mo Y, Lakkis H, Edwards JB, et al. Adjunctive lumateperone in patients with major depressive disorder: results from a randomized, double-blind, phase 3 trial. Am J Psychiatry. 2025;182(12):1072\u201382.","journal-title":"Am J Psychiatry"},{"key":"3630_CR30","unstructured":"PORBITAL. PlotDigitizer. Available from https:\/\/plotdigitizer.com. Accessed 31 Dec 2025."},{"key":"3630_CR31","unstructured":"Cochrane. Risk of Bias 2 (RoB 2) tool. 2025. Available from: https:\/\/methods.cochrane.org\/risk-bias-2. Accessed 12 Dec 2025."},{"issue":"5","key":"3630_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1600-0447.1986.tb02723.x","volume":"73","author":"J Davidson","year":"1986","unstructured":"Davidson J, Turnbull CD, Strickland R, Miller R, Graves K. The Montgomery\u2010\u00c5sberg Depression Scale: reliability and validity. Acta Psychiatr Scand. 1986;73(5):544\u20138.","journal-title":"Acta Psychiatr Scand"},{"issue":"7","key":"3630_CR33","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The Clinical Global Impressions Scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28.","journal-title":"Psychiatry (Edgmont)"},{"key":"3630_CR34","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. 2011."},{"issue":"4","key":"3630_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.jval.2011.01.011","volume":"14","author":"DC Hoaglin","year":"2011","unstructured":"Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011;14(4):429\u201337.","journal-title":"Value Health"},{"issue":"4","key":"3630_CR36","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jval.2011.04.002","volume":"14","author":"JP Jansen","year":"2011","unstructured":"Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1. Value Health. 2011;14(4):417\u201328.","journal-title":"Value Health"},{"issue":"1","key":"3630_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1465-9921-14-100","volume":"14","author":"S Cope","year":"2013","unstructured":"Cope S, Donohue JF, Jansen JP, Kraemer M, Capkun-Niggli G, Baldwin M, et al. Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res. 2013;14(1):100.","journal-title":"Respir Res"},{"key":"3630_CR38","unstructured":"SourceForge. JAGS: Just another Gibbs sampler (2022). Available from: https:\/\/mcmc-jags.sourceforge.io. Accessed 12 Dec 2025."},{"key":"3630_CR39","unstructured":"ClinicalTrials.gov. Clinical trial of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder. NCT04985942. Updated May 2025. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04985942. Accessed 23 June 2025."},{"key":"3630_CR40","unstructured":"ClinicalTrials.gov. Multicenter study of lumateperone as adjunctive therapy in the treatment of patients with major depressive disorder. NCT05061706. Updated May 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05061706. Accessed 23 June 2025."},{"issue":"1","key":"3630_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1176\/appi.ajp.20230922","volume":"181","author":"RS McIntyre","year":"2024","unstructured":"McIntyre RS, Kwan ATH, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry. 2024;181(1):26\u201338.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"3630_CR42","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/acps.13758","volume":"151","author":"R De","year":"2025","unstructured":"De R, Smith ECC, Navagnanavel J, Au E, Maksyutynska K, Papoulias M, et al. The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta-analysis. Acta Psychiatr Scand. 2025;151(2):109\u201326.","journal-title":"Acta Psychiatr Scand"},{"issue":"9","key":"3630_CR43","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.033610","volume":"13","author":"Z Cai","year":"2024","unstructured":"Cai Z, Chen G, Zhao W, Wei Z, Wang X, Huang Z, et al. Increased risk of cardiometabolic disease in ideal weight adults with history of overweight\/obesity in China: a prospective cohort study. J Am Heart Assoc. 2024;13(9):e033610.","journal-title":"J Am Heart Assoc"},{"key":"3630_CR44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1951","volume":"361","author":"R Gafoor","year":"2018","unstructured":"Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years\u2019 follow-up: population based cohort study. BMJ. 2018;361:k1951.","journal-title":"BMJ"},{"key":"3630_CR45","unstructured":"Patel J, Marwaha R. Akathisia. In: StatPearls. Treasure Island. 2025."},{"issue":"2","key":"3630_CR46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","volume":"37","author":"L Citrome","year":"2017","unstructured":"Citrome L. Activating and sedating adverse effects of second-generation antipsychotics in the treatment of Schizophrenia and Major Depressive Disorder: absolute risk increase and number needed to harm. J Clin Psychopharmacol. 2017;37(2):138\u201347.","journal-title":"J Clin Psychopharmacol"},{"key":"3630_CR47","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.jad.2024.10.040","volume":"369","author":"L Citrome","year":"2025","unstructured":"Citrome L, Reda I, Kerolous M. Adjunctive cariprazine for the treatment of Major Depressive Disorder: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2025;369:1238\u201347.","journal-title":"J Affect Disord"},{"key":"3630_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413289","author":"M Sowa-Kucma","year":"2024","unstructured":"Sowa-Kucma M, Panczyszyn-Trzewik P, Jaeschke RR. Exploring the pharmacological and clinical features of Lumateperone: a promising novel antipsychotic. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252413289.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3630_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1176\/appi.ajp-rj.2023.180306","volume":"18","author":"T DePietro","year":"2023","unstructured":"DePietro T. Lumateperone: a truly innovative antipsychotic medication? Am J Psychiatry Residents J. 2023;18(3):18\u201320.","journal-title":"Am J Psychiatry Residents J"},{"issue":"1","key":"3630_CR50","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/YIC.0000000000000011","volume":"29","author":"M Bauer","year":"2014","unstructured":"Bauer M, Demyttenaere K, El-Khalili N, Thase ME, Papakostas GI, Szamosi J, et al. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with Major Depressive Disorder according to ongoing SSRI or SNRI treatment. Int Clin Psychopharmacol. 2014;29(1):16\u201325.","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"3630_CR51","first-page":"344","volume":"11","author":"JC Nelson","year":"2009","unstructured":"Nelson JC, Thase ME, Trivedi MH, Fava M, Han J, Van Tran Q, et al. Safety and tolerability of adjunctive aripiprazole in major depressive disorder: a pooled post hoc analysis (studies CN138-139 and CN138-163). Prim Care Companion J Clin Psychiatry. 2009;11(6):344\u201352.","journal-title":"Prim Care Companion J Clin Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03630-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03630-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:16Z","timestamp":1787385856000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03630-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3630"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03630-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andrew J. Cutler has served as a consultant and advisory board member to AbbVie, Acadia, Actinogen, Alfasigma, Alkermes, Anavex Life Sciences, Arrivo BioVentures, Autobahn Therapeutics, Axsome, Aytu Biopharma, BioXcel, Boehringer Ingelheim, Bristol Myers Squibb, Collegium Pharmaceutical, Corium, Definium Therapeutics, 4\u00a0M Therapeutics, Helus Pharma, Incannex Healthcare, Helus Pharma, Incannex Healthcare, Intra-Cellular Therapies, J&J Innovative Medicine, Jazz Pharma, Knight Therapeutics, Kye Pharmaceuticals, Kuvatris Therapeutics, LivaNova, Lundbeck, Luye Pharma, MapLight Therapeutics, Mentavi, Neumora, Neurocrine Biosciences, NeuroSigma, Noven, Otsuka, Relmada, Sensorium Therapeutics, Sirtsei Pharmaceuticals, Supernus, Teva, Thynk, Transneural Therapeutics, Tris Pharma, Vanda Pharmaceuticals, and Vistagen; has participated in speakers bureau activities for AbbVie, Alfasigma, Alkermes, Axsome, Aytu Biopharma, Boehringer Ingelheim, Bristol Myers Squibb, Collegium Pharmaceutical, Corium, Intra-Cellular Therapies, J&J Innovative Medicine, Knight Therapeutics, Kye Pharmaceuticals, Lundbeck, Luye Pharma, Neurocrine Biosciences, Noven, Otsuka, Supernus, Teva, Tris Pharma, and Vanda Pharmaceuticals; has served on a data safety monitoring board for Compass Pathways; and hold stock options\/equity in EMA Wellness, Evolution Research Group, 4\u00a0M Therapeutics, Sensorium Therapeutics, Transneural Therapeutics. Qiaoyi Zhang, Carol Mao, Mahmoud Hashim, Madhav Namjoshi, and John J. Sheehan, are employees of Johnson and Johnson Innovative Medicine. Ana\u00efs Lemyre, Todor I. Totev, Marjolaine Gauthier-Loiselle, Yujie Wu, Jingyi Liu, Dominic Pilon, and Patrick Lefebvre are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson and Johnson Innovative Medicine, which funded the development and conduct of this study and manuscript. Leslie Citrome has served as a consultant for Abbvie, Acadia, Adheretech, Altus, Alumis, Axsome, Alkermes, Arc, Auritec, Autobahn, Avant Healthcare Solutions,  Biogen, BioXcel, BMS\/Karuna, Boehringer Ingelheim, Cadent, Cerevel,  Clario\/Medavante\/Prophase, Clinilabs, Compass, Corcept, Definium, Delpor, Eisai, Enteris BioPharma, Health Wellness Partners, HLS, Idorsia, Inmune Bio, Intra-Cellular, Johnson & Johnson\/Janssen, Little Bear, Lundbeck, Luye, Lyndra, Maplight, Marvin, Mindmed, Neurelis,  Neushen, Neumora, Neurocrine, Noema, Novartis, Noven, Orexo, Otsuka, Ovid, Pontifax\/Draig, Praxis, PSL, Real Chemistry, Relmada, Renew Research, Response, Reviva, Sage, Seaport, Sumitomo\/Sunovion, Supernus, Teva, University of Arizona, Vanda, Wells-Fargo, and one-off ad hoc consulting for individuals\/entities conducting marketing, commercial, or scientific scoping research; speaker for Abbvie, Acadia, Alkermes, BMS, Eisai, Idorsia, Intra-Cellular, Johnson & Johnson\/Janssen, Lundbeck, Luye, Neopharm, Neurocrine, Noven, Otsuka, Recordati, Takeda, Teva, Vanda, and CME activities organized by medical education companies such as Decera Clinical Education\/Clinical Education Alliance\/Clinical Care Options, CME Institute, CMEology, HMP\/Psych Congress, Medscape\/WebMD, MultiMedia Medical LLC, Neuroscience Education Institute, NEI, Paradigm, Real Psychiatry\/Efficient, Real World CE, Rockpointe, Total CME, Vindico, and Universities, Professional Organizations\/Societies and Advocacy Associations (MHA); owns small amounts of health-related shares of common stock in multiple companies in a portfolio managed externally, and stock options in Reviva; and earns royalties\/publishing income from Taylor & Francis (Editor-in-Chief, Current Medical Research and Opinion, 2022-date), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics, through Spring 2025).","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required because this is a secondary analysis of summary\u2011level data based on previously conducted studies and does not include any new studies involving human participants or animals conducted by any of the authors.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}